PROCEPT BioRobotics Corp (PRCT) Stock
PRCT has an Alpha Score of 28 out of 100 (poor), computed on Nov 5, 2026 from 2 of 4 sub-scores. 3 of the hedge funds AlphaScala tracks reported PRCT in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Millennium Management's at $14.10M. Company insiders reported 0 open-market buys and 4 sales on SEC Form 4 in the 90 days to Nov 10, 2026.
What is PRCT's Alpha Score?
How it works →Alpha Score of 28 reflects poor overall profile with weak momentum, weak quality. Based on 2 of 4 signals – score is capped at 75 until remaining data ingests.
Computed from 2 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Nov 5, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which hedge funds own PRCT?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Millennium Management Israel Englander | 624K | $14.10M | -38% |
| Marshall Wace | 297K | $6.71M | -57% |
| Citadel Ken Griffin | 13K | $284.8K | NEW |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are PROCEPT BioRobotics Corp insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Nov 6, 26 | Sharma Pooja | Chief Strat/Marketing Officer | SELL | 4.7K | $93K |
| Sep 9, 26 | Templin Barry L | EVP, Chief Technology Officer | SELL | 373 | $8K |
| Sep 9, 26 | Nouri Alaleh | EVP, CLO, CORP. SEC. | SELL | 297 | $6K |
| Sep 9, 26 | Waters Kevin | EVP, CFO | SELL | 373 | $8K |
| Aug 7, 26 | Wood Larry L | President, CEO | BUY | 23.9K | $498K |
SEC Form 4 filings as of Nov 10, 2026
See cluster-buy signals across all tickers →What are PRCT's key statistics?
Key statistics as of Oct 29, 2026
How does PRCT's valuation compare with the Healthcare sector?
| Metric | PRCT | Healthcare median | Companies in median |
|---|---|---|---|
| Net margin | -32.54% | 3.60% | 175 |
| Return on equity | -30.62% | 2.93% | 201 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 11, 2026). P/E excludes loss-making companies.
PRCT price chart
Powered by TradingViewWhat does PROCEPT BioRobotics Corp do?
PROCEPT BioRobotics Corporation is a surgical robotics company specializing in minimally invasive urologic treatments. The company develops and manufactures the AquaBeam Robotic System and HYDROS Robotic System, which deliver Aquablation therapy—a heat-free, waterjet-based treatment for benign prostatic hyperplasia (BPH). These image-guided, computer-assisted platforms combine real-time multidimensional imaging with personalized treatment planning and automated robotics to precisely remove prostate tissue while preserving sexual function and continence across prostates of all shapes and sizes. The Aquablation therapy approach is clinically proven to provide significant, long-lasting symptom relief. PROCEPT BioRobotics operates through a recurring-revenue business model, generating income from both robotic system sales and consumable handpieces used in procedures. The company serves urologists and patients in the United States and internationally, addressing a substantial market opportunity in men's health and lower urinary tract symptoms. Founded in 2007 and headquartered in San Jose, California, PROCEPT BioRobotics continues to expand its installed base of robotic systems while advancing clinical applications, including investigational studies for localized prostate cancer treatment.